vs
Side-by-side financial comparison of UNIVERSAL DISPLAY CORP \PA\ (OLED) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
UNIVERSAL DISPLAY CORP \PA\ is the larger business by last-quarter revenue ($142.2M vs $75.5M, roughly 1.9× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -14.5%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -5.3%).
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
OLED vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $142.2M | $75.5M |
| Net Profit | $35.9M | — |
| Gross Margin | 74.6% | 69.3% |
| Operating Margin | 30.1% | 22.7% |
| Net Margin | 25.2% | — |
| Revenue YoY | -14.5% | 27.7% |
| Net Profit YoY | -44.3% | — |
| EPS (diluted) | $0.76 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $142.2M | — | ||
| Q4 25 | $172.9M | $75.5M | ||
| Q3 25 | $139.6M | $54.5M | ||
| Q2 25 | $171.8M | $52.4M | ||
| Q1 25 | $166.3M | $46.0M | ||
| Q4 24 | $162.3M | $59.1M | ||
| Q3 24 | $161.6M | $80.5M | ||
| Q2 24 | $158.5M | $47.1M |
| Q1 26 | $35.9M | — | ||
| Q4 25 | $66.3M | — | ||
| Q3 25 | $44.0M | $8.8M | ||
| Q2 25 | $67.3M | $5.9M | ||
| Q1 25 | $64.4M | $3.0M | ||
| Q4 24 | $46.0M | — | ||
| Q3 24 | $66.9M | $20.3M | ||
| Q2 24 | $52.3M | $-4.5M |
| Q1 26 | 74.6% | — | ||
| Q4 25 | 76.1% | 69.3% | ||
| Q3 25 | 74.6% | 77.7% | ||
| Q2 25 | 77.2% | 76.5% | ||
| Q1 25 | 77.1% | 77.1% | ||
| Q4 24 | 77.0% | 76.4% | ||
| Q3 24 | 77.8% | 63.9% | ||
| Q2 24 | 75.8% | 77.4% |
| Q1 26 | 30.1% | — | ||
| Q4 25 | 38.9% | 22.7% | ||
| Q3 25 | 30.9% | 17.6% | ||
| Q2 25 | 39.9% | 12.7% | ||
| Q1 25 | 41.9% | 8.7% | ||
| Q4 24 | 32.3% | 22.6% | ||
| Q3 24 | 41.5% | 27.4% | ||
| Q2 24 | 35.6% | -4.6% |
| Q1 26 | 25.2% | — | ||
| Q4 25 | 38.4% | — | ||
| Q3 25 | 31.5% | 16.2% | ||
| Q2 25 | 39.2% | 11.2% | ||
| Q1 25 | 38.8% | 6.5% | ||
| Q4 24 | 28.4% | — | ||
| Q3 24 | 41.4% | 25.2% | ||
| Q2 24 | 33.0% | -9.6% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $1.40 | $0.26 | ||
| Q3 25 | $0.92 | $0.17 | ||
| Q2 25 | $1.41 | $0.12 | ||
| Q1 25 | $1.35 | $0.06 | ||
| Q4 24 | $0.96 | $0.40 | ||
| Q3 24 | $1.40 | $0.41 | ||
| Q2 24 | $1.10 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $516.4M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | — | $130.3M |
| Total Assets | $1.9B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $516.4M | — | ||
| Q4 25 | $602.4M | $97.5M | ||
| Q3 25 | $603.0M | $94.4M | ||
| Q2 25 | $525.2M | $96.0M | ||
| Q1 25 | $571.3M | $93.2M | ||
| Q4 24 | $492.7M | $101.0M | ||
| Q3 24 | $551.6M | $96.7M | ||
| Q2 24 | $530.5M | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $130.3M | ||
| Q3 25 | $1.7B | $115.3M | ||
| Q2 25 | $1.7B | $104.7M | ||
| Q1 25 | $1.7B | $97.1M | ||
| Q4 24 | $1.6B | $92.1M | ||
| Q3 24 | $1.6B | $71.1M | ||
| Q2 24 | $1.5B | $48.5M |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.0B | $216.3M | ||
| Q3 25 | $1.9B | $202.9M | ||
| Q2 25 | $1.9B | $194.9M | ||
| Q1 25 | $1.9B | $196.2M | ||
| Q4 24 | $1.8B | $213.3M | ||
| Q3 24 | $1.8B | $220.7M | ||
| Q2 24 | $1.8B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.9M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 3.03× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $108.9M | — | ||
| Q4 25 | $31.1M | $14.4M | ||
| Q3 25 | $97.2M | $9.7M | ||
| Q2 25 | $51.9M | $14.1M | ||
| Q1 25 | $30.6M | $3.6M | ||
| Q4 24 | $34.7M | $15.6M | ||
| Q3 24 | $79.9M | $11.0M | ||
| Q2 24 | $67.0M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $15.1M | $14.4M | ||
| Q3 25 | $84.3M | $9.7M | ||
| Q2 25 | $37.5M | $14.1M | ||
| Q1 25 | $17.5M | $3.6M | ||
| Q4 24 | $22.0M | $15.6M | ||
| Q3 24 | $66.2M | $11.0M | ||
| Q2 24 | $57.9M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | 19.1% | ||
| Q3 25 | 60.4% | 17.7% | ||
| Q2 25 | 21.8% | 26.8% | ||
| Q1 25 | 10.5% | 7.7% | ||
| Q4 24 | 13.6% | 26.4% | ||
| Q3 24 | 41.0% | 13.7% | ||
| Q2 24 | 36.5% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 9.3% | 0.0% | ||
| Q3 25 | 9.2% | 0.0% | ||
| Q2 25 | 8.4% | 0.0% | ||
| Q1 25 | 7.9% | 0.1% | ||
| Q4 24 | 7.8% | 0.0% | ||
| Q3 24 | 8.4% | 0.0% | ||
| Q2 24 | 5.8% | 0.0% |
| Q1 26 | 3.03× | — | ||
| Q4 25 | 0.47× | — | ||
| Q3 25 | 2.21× | 1.10× | ||
| Q2 25 | 0.77× | 2.41× | ||
| Q1 25 | 0.47× | 1.21× | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | 1.19× | 0.54× | ||
| Q2 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
PBYI
Segment breakdown not available.
